Diagnostic Challenges in Pleural Mesothelioma

Our plain-English summary of Diagnostic Challenges in Pleural Mesothelioma, by M. Lapidot, M. Sattler (Cancers, 2026).

The study

• Authors: M. Lapidot, M. Sattler
• Journal: Cancers
• Published: 2026;18(9)
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

Accurate diagnosis of PM and precise histologic subtyping are critical for optimal therapeutic decision-making, as treatment strategies-including chemotherapy, immunotherapy, or multimodality approaches-are largely subtype-dependent. Because of the several-decade latency between fiber inhalation and symptom onset, many cases are diagnosed at an advanced stage, when patients are already in poor clinical condition. As observed across multiple solid malignancies, earlier-stage diagnosis is associated with improved prognosis and expanded therapeutic options. However, the rarity of PM, the absence of validated screening strategies, and its nonspecific clinical and radiologic presentation-often mimicking both benign and metastatic pleural conditions, frequently result in diagnostic delay. Furthermore, the lack of pathognomonic histopathologic markers further complicates timely and definitive diagnosis. This review aims to delineate the epidemiologic, clinical, radiologic, and pathologic barriers that hinder accurate and early detection of PM. Current clinical evidence points to an urgent need to develop novel, validated biomarkers in PM, which will require a multidisciplinary approach.

In plain English

This article was a review, not a new study: the authors stated that no new data were created or analyzed. It described why pleural mesothelioma is hard to detect early and diagnose accurately. Citing published work, the authors gave a United States incidence of about 1 per 100,000, a risk of about 1–10% after heavy asbestos exposure, and symptoms typically appearing 20–50 years after exposure. In one cited screening study, low-dose CT detected malignancy in 2.1% of 516 high-risk people, and the authors reported a consensus that evidence is insufficient to justify screening asymptomatic asbestos-exposed people. Reviewed figures put pleural fluid cytology sensitivity at 30–75%, against 93% sensitivity and 100% specificity for thoracoscopic biopsy. In a cited series of 147 surgical patients, preoperative and postoperative biphasic diagnoses agreed in only 83. Candidate blood and breath markers gave varying results across studies; fibulin-3 reached only 11.9% sensitivity in a later study. The authors concluded that attempts to find reliable early-detection biomarkers have so far been unsuccessful.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published literature and guidelines on diagnosing pleural mesothelioma; no new data
• Who was studied: No patients were studied directly. The review covered published studies, screening programs and guidelines on pleural mesothelioma diagnosis.
• Exposure: Asbestos exposure in general, discussed as the main established cause of pleural mesothelioma. The article does not name specific fiber types.
• Main results:
  • Citing other studies, the authors gave an incidence of approximately 1 per 100,000 individuals in the United States (nearly 3300 new cases annually).
  • Citing other studies, the authors described the risk of developing pleural mesothelioma after heavy exposure as relatively small (about 1–10%), and smaller still for primarily environmental exposure.
  • Symptoms typically emerge 20–50 years after exposure.
  • In one cited screening study of 516 high-risk asbestos-exposed individuals, low-dose CT detected malignancy in 2.1% (2 pleural mesothelioma, 6 lung cancers, 2 peritoneal mesothelioma).
  • The authors reported a consensus in the literature that there is currently insufficient evidence to justify screening asymptomatic individuals with known asbestos exposure.
  • In the review's table, pleural effusion cytology was given a sensitivity of 30–75% and a specificity of 99–100%.
  • Video-assisted thoracoscopic (VATS) pleural biopsy was described as achieving 93% sensitivity and 100% specificity.
  • In a cited study of 147 consecutive patients undergoing pleurectomy decortication, preoperative and postoperative biphasic diagnoses agreed in only 83 patients. Before surgery, 60 patients (40.7%) had been classified as epithelioid and 4 (2.7%) as sarcomatoid.
  • Loss of BAP1 on immunohistochemistry was described as having specificity near 100% but moderate sensitivity (60–69%) for malignancy.
  • Plasma fibulin-3 initially showed 100% sensitivity and specificity, but a later prospective study reported a sensitivity of only 11.9% and an AUC of 0.51.
  • Results for candidate biomarkers varied across studies, which the authors attributed to differences in sample type, control groups, histological subtypes, cohort size and methods.
• The authors' conclusion: The authors concluded that attempts to identify reliable biomarkers for early detection of pleural mesothelioma have been unsuccessful so far. They called for multinational, multi-institutional collaboration to validate candidate biomarkers.
• Limitations the authors state:
  • The authors noted that research on the evidence they reviewed is limited: the disease's rarity makes recruitment difficult, resulting in small, underpowered studies.

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Chemotherapy, Immunotherapy, Latency, Prognosis, Biomarker, Multidisciplinary Team.

Related studies

• MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities — L. Nicolè, F. Cappello, et al. (2019)
• Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma — J. Moro, S. Sobrero, et al. (2022)
• Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma — S. Lucà, G. Pignata, et al. (2025)
• The diagnostic challenge of peritoneal mesothelioma — P. Krasuski, A. Poniecka, et al. (2002)
• Signet ring cell mesothelioma; A diagnostic challenge — H. Wang, C. Herath (2019)
• Malignant peritoneal mesothelioma-a diagnostic challenge — S. Abdul Razzak, F. Awan, et al. (2022)

Browse more research in Cancers, or return to medical research.